title: [The efficacy of BFM-90 program in the treatment of acute lymphoblastic leukemia in children in the studies of Polish pediatric leukemia/lymphoma group].
abstract: Between years 1993 and 1998, 113 children aged from 6 months to 18 years (41 girls and 72 boys) with first relapse of acute lymphoblastic leukaemia (ALL) were included in the study. All children were treated according to BFM-90 relapse protocol. Thirty-two cases were classified as very early relapses, 56 as early and 25 as late relapses. Sixty-one children had isolated bone marrow relapse, in 30 children extramedullary relapse occurred (in 21 children in central nervous system and in 16 children in testes). There were 23 combined relapses. Remission was achieved in 12 children with very early relapse (78.12%), 32 children with early relapse (85.71) and 19 children with late relapse (96%). Event-free survival in 30 months of follow-up was 29.2%, 59.0% and 73.2% for very early, early and late relapses, respectively. Sixteen children with relapsed ALL after chemotherapy according to BFM-90 relapse protocol underwent high-dose therapy with hematopoietic stem cell transplantation (in 3 cases autologous and in 13 cases allogeneic). In 6 children isolated bone marrow relapse occurred after transplantation, all of them died during subsequent chemotherapy. Ten children is alive and well from 2 to 43 months after transplantation. The results obtained with BFM-90 chemotherapy in children with first early relapses are not acceptable. Such patients require high-dose chemotherapy and transplantation of hematopoietic progenitor cells.
authors.affiliation: Kliniki Hematologii i Chorób Rozrostowych Dzieci Akademii Medycznej we Wrocławiu.
authors.forename: A
authors.initials: A
authors.lastname: Chybicka
authors.forename: J
authors.initials: J
authors.lastname: Bogusławska-Jaworska
authors.forename: E
authors.initials: E
authors.lastname: Gorczyńska
authors.forename: K
authors.initials: K
authors.lastname: Juszczak
authors.forename: J
authors.initials: J
authors.lastname: Armata
authors.forename: A
authors.initials: A
authors.lastname: Balcerska
authors.forename: W
authors.initials: W
authors.lastname: Balwierz
authors.forename: H
authors.initials: H
authors.lastname: Bubała
authors.forename: B
authors.initials: B
authors.lastname: Filiks-Litwin
authors.forename: P
authors.initials: P
authors.lastname: Kołecki
authors.forename: J
authors.initials: J
authors.lastname: Kowalczyk
authors.forename: K
authors.initials: K
authors.lastname: Lukowska
authors.forename: M
authors.initials: M
authors.lastname: Matysiak
authors.forename: R
authors.initials: R
authors.lastname: Rokicka-Milewska
authors.forename: E
authors.initials: E
authors.lastname: Rola-Kurc
authors.forename: D
authors.initials: D
authors.lastname: Stencel
authors.forename: D
authors.initials: D
authors.lastname: Sońta-Jakimczyk
authors.forename: W
authors.initials: W
authors.lastname: Strojny
authors.forename: J
authors.initials: J
authors.lastname: Wachowiak
authors.forename: M
authors.initials: M
authors.lastname: Wieczorek
authors.forename: M
authors.initials: M
authors.lastname: Wysocki
authors.forename: E
authors.initials: E
authors.lastname: Zelenay
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local; D011044:Poland; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000628:therapy*; D011241:Prednisone / Q000008:administration & dosage; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin